title: Duration of dialysis and its relationship to dialysis adequacy, anemia management, and serum albumin level.
abstract: An analysis of the relationship between intermediate outcomes and duration of dialysis therapy in hemodialysis patients was performed by linking Health Care Financing Administration (HCFA) Core Indicators data with data obtained from HCFA form 2728 at the initiation of dialysis therapy. Patients who recently initiated hemodialysis therapy were less likely to meet Dialysis Outcomes Quality Initiative guidelines than patients with a longer duration of dialysis therapy. For both urea reduction ratio and Kt/V, odds ratios for adequate dialysis were approximately 0.20 for a duration of dialysis therapy less than 0.5 years and 0.42 to 0.63 for a duration of dialysis therapy of 0.5 to 1.0 years compared with a duration of dialysis therapy of 2.0 years or greater. For patients with a duration of dialysis therapy less than 0.5 years (compared with >/=2.0 years), the odds ratio for a hematocrit less than 28% was approximately 3.0, that for a hematocrit 33% or greater was approximately 0.6, and that for a serum albumin level of 3.5 g/dL or greater (bromcresol green method) or 3.2 g/dL or greater (bromcresol purple method) was approximately 0.4. There was a direct relationship between glomerular filtration rate at the initiation of dialysis therapy and both serum albumin and hematocrit values. Patients administered recombinant human erythropoietin (rHuEPO) predialysis were more likely to have greater hematocrits. There also was a direct relationship between hematocrit and serum albumin level. Therefore, several actionable items in regard to attentive overall medical care can result in an improvement in the percentage of patients newly started on hemodialysis therapy who meet intermediate outcomes, including the administration of rHuEPO predialysis, correction of iron deficiency, and timely placement of a permanent dialysis access.
authors.affiliation: Section on Nephrology, Wake Forest University School of Medicine, Winston-Salem, NC 27157-1053, USA. mrocco@wfubmc.edu
authors.forename: M V
authors.initials: MV
authors.lastname: Rocco
authors.forename: M R
authors.initials: MR
authors.lastname: Bedinger
authors.forename: R
authors.initials: R
authors.lastname: Milam
authors.forename: J W
authors.initials: JW
authors.lastname: Greer
authors.forename: W M
authors.initials: WM
authors.lastname: McClellan
authors.forename: D L
authors.initials: DL
authors.lastname: Frankenfield
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000740:Anemia / Q000097:blood / Q000208:ethnology / Q000628:therapy; D015415:Biomarkers / Q000097:blood; D003627:Data Interpretation, Statistical; D004921:Erythropoietin / Q000008:administration & dosage; D005260:Female; D019983:Guideline Adherence; D006400:Hematocrit / Q000592:standards*; D006801:Humans; D007501:Iron / Q000008:administration & dosage; D007676:Kidney Failure, Chronic / Q000097:blood / Q000208:ethnology / Q000628:therapy*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D017410:Practice Guidelines as Topic; D011994:Recombinant Proteins; D006435:Renal Dialysis / Q000592:standards*; D012307:Risk Factors; D012709:Serum Albumin / Q000032:analysis; D013997:Time Factors; D016896:Treatment Outcome; D014508:Urea / Q000097:blood
chemical_list: D015415:Biomarkers; D011994:Recombinant Proteins; D012709:Serum Albumin; D004921:Erythropoietin; D014508:Urea; D007501:Iron